Geron receives milestone payment from merck triggered by ind filing for telomerase cancer vaccine candidate
- Category: Vaccines
- Published on Thursday, 13 December 2007 11:37
- Hits: 1727
Geron Corporation announced today that Merck & Co, Inc. has filed an Investigational New Drug application with the U.S. Food and Drug Administration for a cancer vaccine candidate that targets telomerase
MENLO PARK, CA, USA | December 12, 2007 | Geron Corporation (Nasdaq: GERN) announced today that Merck & Co, Inc. has filed an Investigational New Drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for a cancer vaccine candidate that targets telomerase. Merck is developing the vaccine under a July, 2005 Research, Development and Commercialization License Agreement with Geron, which provided Merck with exclusive worldwide rights to develop and commercialize non-dendritic cell based vaccines targeting telomerase. Geron has received a $4 million milestone payment from Merck on account of the IND filing, and is eligible to receive additional development milestones as well as royalties on worldwide product sales. “We are pleased with the progress that Merck has made in advancing this program towards the clinic,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer. “We appreciate the collaborative nature of our relationship with Merck and look forward to working with them to realize the therapeutic potential of this cancer vaccine candidate.”
Geron’s Dendritic Cell-Based Cancer Vaccine
Separately, Geron is currently enrolling patients with acute myelogenous leukemia (AML) in a Phase I/II study of its own telomerase vaccine candidate, GRNVAC1, which delivers the telomerase antigen using autologous dendritic cells. In a prior study conducted at Duke University, the vaccine was shown to induce substantial T-cell anti-telomerase activity. The Geron study also incorporates a prime/boost vaccine dosing regimen designed to prolong the period of anti-telomerase immunity. Geron is also developing a second generation allogeneic telomerase vaccine based on dendritic cells made from human embryonic stem cells.
Telomerase and Cancer
Telomerase is an enzyme, active in most cancer cells, that maintains telomere length at the ends of chromosomes. This activity confers replicative immortality to the cells in the tumor, allowing the cancer to grow and metastasize over long periods of time. Because telomerase is inactive or only transiently expressed in normal human tissues, and is critical to the growth and progression of most cancer types, it is regarded as a universal and specific cancer target. Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
SOURCE: Geron Corporation